← Leaderboards
Rozenn Lemaitre
University Of Washington
$11,661,963
Attributed
$15,389,493
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,389,493 · 8
By mechanism
R01$15,389,493 · 8
Top collaborators
- Rheem Angela Totah8 shared
- Dan E Arking2 shared
- Juan Troncoso2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Wesley C Van Voorhis$32,631,211
- Judith N. Wasserheit$2,842,926
- Teal S Hallstrand$15,720,308
- Junko Oshima$3,761,782
- Rheem Angela Totah$7,253,628
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingFutureRisk FactorsInsightPathway InteractionsApoptosisPreventionPalmitic AcidsPlasmaCardiovascular HealthProspectiveCardiovascular DiseasesOxidative StressFatty AcidsFunctional DisorderMetabolicProspective StudiesDiabetes MellitusParticipantSaturated Fatty AcidsBaseMortalityCardiac MyocytesHeart Failure
Grant awards (24)
Circulating and Brain Lipidomics, Cognition and Dementia$754,765
R01 · FY2025 · AG
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$655,186
R01 · FY2025 · HL
Circulating and Brain Lipidomics, Cognition and Dementia$790,242
R01 · FY2024 · AG
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$641,276
R01 · FY2024 · HL
Plasma Sphingolipids and Subclinical and Clinical Cardiovascular Disease$681,019
R01 · FY2023 · HL · contact PI
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$655,329
R01 · FY2023 · HL
Plasma Sphingolipids and Subclinical and Clinical Cardiovascular Disease$691,529
R01 · FY2022 · HL · contact PI
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$673,106
R01 · FY2022 · HL
Circulating sphingolipids and risk and outcomes of ventricular fibrillation$582,469
R01 · FY2022 · HL · contact PI
Plasma Sphingolipids and Subclinical and Clinical Cardiovascular Disease$692,708
R01 · FY2021 · HL · contact PI
Circulating sphingolipids and risk and outcomes of ventricular fibrillation$686,089
R01 · FY2021 · HL · contact PI
Circulating sphingolipids and risk and outcomes of ventricular fibrillation$689,315
R01 · FY2020 · HL · contact PI
Plasma Sphingolipids and Subclinical and Clinical Cardiovascular Disease$676,107
R01 · FY2020 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$668,957
R01 · FY2019 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$696,593
R01 · FY2018 · HL · contact PI
Plasma sphingolipids and risk of cardiovascular disease$443,040
R01 · FY2018 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$702,829
R01 · FY2017 · HL · contact PI
Plasma sphingolipids and risk of cardiovascular disease$587,431
R01 · FY2017 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$701,774
R01 · FY2016 · HL · contact PI
Plasma sphingolipids and risk of cardiovascular disease$565,200
R01 · FY2016 · HL · contact PI
Sphingolipids, Diabetes, and Cardiovascular Disease$477,417
R01 · FY2016 · DK · contact PI
Sphingolipids, Diabetes, and Cardiovascular Disease$534,613
R01 · FY2015 · DK · contact PI
Sphingolipids, Diabetes, and Cardiovascular Disease$527,505
R01 · FY2014 · DK · contact PI
HUMAN GENETIC VARIATION IN FATTY ACID METABOLISM AND SUDDEN CARDIAC ARREST$614,994
R01 · FY2012 · HL · contact PI